RxDoctor Payments DataLook up a doctor →

Megan Edwards, DO

Neurology · Oxford, MSNPI 1336550425

Payments from drug & device makers

$26,500in general payments, 2019–2025

Across 1,543 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$2K
  • Biogen$2K
  • Amgen$1K
  • Jazz Pharmaceuticals Inc.$1K
  • Pfizer$1K
  • plus $17K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)220$2,860
Novartis113$1,717
Biogen78$1,617
Amgen(2 entities)86$1,297
Jazz Pharmaceuticals Inc.56$1,166
Pfizer72$1,088
Lilly USA, LLC63$1,075
EMD Serono, Inc.57$1,010
UCB, Inc.43$1,002
AstraZeneca(2 entities)41$924
Acadia Pharmaceuticals Inc52$861
Lundbeck LLC43$841
SK Life Science, Inc.32$758
Neurocrine Biosciences, Inc.48$738
Teva Pharmaceuticals USA, Inc.43$666
Amneal Pharmaceuticals LLC44$624
Genentech USA, Inc.35$593
Sanofi28$536
Eisai Inc.26$528
Bristol Myers Squibb25$527
Harmony Biosciences LLC21$475
Avanir Pharmaceuticals, Inc.28$408
Tanabe Pharma America, Inc.26$400
Acorda Therapeutics, Inc20$390
Biohaven Pharmaceutical Holding Company Ltd.25$364
Argenx US, Inc.15$348
Biohaven Pharmaceuticals, Inc.24$304
Otsuka America Pharmaceutical, Inc.16$252
Kyowa Kirin, Inc.14$246
Supernus Pharmaceuticals, Inc.15$245
Greenwich Biosciences, Inc.7$238
Neurelis, Inc.11$208
Merz Pharmaceuticals, LLC7$172
Johnson & Johnson19$171
Catalyst Pharmaceuticals, Inc.8$166
Sunovion Pharmaceuticals Inc.7$126
TG Therapeutics, Inc.6$123
Corium, LLC8$118
Merz North America, Inc.5$113
Springworks Therapeutics, Inc.4$108
Livanova USA, Inc.1$93
Mallinckrodt Enterprises LLC5$89
Upsher-smith Laboratories LLC5$86
Vanda Pharmaceuticals Inc.3$80
Kedrion Biopharma, Inc.1$73
CSL Behring4$71
Scilex Pharmaceuticals Inc.3$58
Medtronic2$58
ANI Pharmaceuticals, Inc.3$50
GRT US Holding, Inc.4$41
Sumitomo Pharma America, Inc.2$40
Nevro Corp.2$40
Alnylam Pharmaceuticals Inc.2$39
Boston Scientific1$37
Sanofi-aventis U.S. LLC2$36
GE HealthCare2$35
Assertio Therapeutics, Inc.2$24
Averitas Pharma Inc.1$24
Mallinckrodt Hospital Products Inc.1$23
Piramal Critical Care1$19

How this compares

$26,500 in reported general payments places this provider in the 80th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi →

Medicare billing

Part B allowed, 2024
$1,434,990
Medicare patients
765
Services billed
71,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Oxford

See the full list for Mississippi →

Where these figures come from

Is this you, or does something look wrong? →